BRCA1/2 Mutations Appear Embryo-Lethal Unless Rescued by Low (CGG n<26) FMR1 Sub-Genotypes: Explanation for the "BRCA Paradox"?

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Weghofer, Andrea ^a,b   Tea, Muy Kheng ^c   Barad, David H ^a,d   Kim, Ann ^a   Singer, Christian F ^c   Wagner, Klaus ^e   Gleicher, Norbert ^a,d  

^a CENTER FOR HUMAN REPRODUCTION   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^d Foundation for Reproductive Medicine   (United States)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO DEATH; FEMALE; FEMALE INFERTILITY; FMR1 GENE; GENE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; OVARIAN RESERVE; OVARY CANCER; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

5' UNTRANSLATED REGIONS; ADULT; ALLELES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; GENE EXPRESSION REGULATION; GENES, BRCA1; GENES, BRCA2; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MODELS, GENETIC; MUTATION; RISK;

EID: 84866340519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044753     Document Type: Article

References (35)

1. Willemsen R, Levenga J, Oostra BA, (2011) CGG repeat in the FMR1 gene: size matters. Clin Genet 80: 214-25.
2. Wittenberger MD, Hagerman RJ, Sherman SL, McConkie-Rosell A, Welt CK, et al. (2007) The FMR1 premutation and reproduction. Fertil Steril 87: 456-465.
3. Gleicher N, Weghofer A, Barad DH, (2010) Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reprod Biomed Online 20: 768-75.
4. Gleicher N, Weghofer A, Lee IH, Barad DH, (2010) FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance. PLoS ONE 5: e15303.
5. Gleicher N, Weghofer A, Barad DH, (2010) Effects of race/ethnicity on triple CGG counts in the FMR1 gene in infertile women and egg donors. Reprod Biomed Online 20: 485-491.
6. Gleicher N, Weghofer A, Lee IH, Barad DH, (2011) Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS ONE 6: e18781.
7. Chen LS, Tassone FT, Sahota P, Hagerman PJ, (2003) The (CGG)n repeat element within the 5' untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum Molec Genet 12: 3067-74.
8. Oktay K, Kim JY, Barad D, Babayev SN, (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28: 240-4.
9. Wagner T, Stoppa-Lyonnet D, Fleischmann E, Muhr D, Pages S, et al. (1999) Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62: 369-76.
10. Sanger F, Nickelen S, Coulson R, (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-7.
11. Petek E, Kroisel PM, Schuster M, Zierler H, Wagner K, (1999) Mosaicism in a fragile X male including a de novo deletion in the FMR1 gene. Am. J Med Genet 84: 229-32.
12. Evers B, Jonkers J, (2006) Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25: 5885-97.
13. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA, (1997) p53 mutations in BRCA1-associated familial breast cancer. Lancet 350: 638-9.
14. Xu CF, Chambers JA, Nicolai H, Brown MA, Hujeirat Y, et al. (1997) Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Genes Chromosomes Cancer 18: 102-10.
15. Cao L, Li W, Kim S, Brodie SG, Deng CX, (1993) Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 17: 201-13.
16. Hakem R, de la Pompa JL, Elia A, Potter J, Mark TW, (1997) Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 16: 298-302.
17. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A, (1997) Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11: 1226-41.
18. Krausz C, (2012) An encore for the repeats: New insights into an old genetic variant. J Clin Endocrinol Metab 97: 764-767.
19. Gleicher N, Barad DH, (2007) Gender as risk factor for autoimmune diseases. J Autoimmun 28: 1-6.
20. Davis-Dao C, Koh CJ, Hardy BE, Chang A, Kim SS, et al. (2012) Shorter androgen receptor CAG repeat lengths associated with cryptorchidism risk among Hispanic white boys. J Clin Endocrinol Metab 97;E393-E399.
21. Gleicher N, Weghofer A, Barad DH, (2012) Cutting edge assessment of the impact of autoimmunity on female reproductive success. J Autoimmun 38: J74-J80.
22. Altekruse SF, Kosary CL, Krapcho M,et al. SEER Cancer Statistics Review 1975-2007, Bethesda, MD, National Cancer Institute (Accessed at http://seer.cancer.gov/csr/1975_2007/.).
23. Campeau PM, Foulkes WD, Tischkowitz MD, (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Human Genetics 124: 31-42.
24. Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, et al. (2007) Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 44: 467-71.
25. Thompson D, Easton DF, (2002) Cancer Incidence in BRCA1 mutation carriers. J Nat Cancer Inst 94: 1358-65.
26. The Breast Cancer Linkage Consortium, (1999) Cancer risks in BRCA2 mutation carriers. J Nat Cancer Inst 91: 1310-6.
27. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, et al. (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21: 1-18.
28. John EM, Miron A, Gong G, Phipps AI, Felberg A, et al. (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298: 2869-76.
29. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, et al. (2007) BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25: 4635-41.
30. Malone KE, Daling JR, Doody DR, Hsu L, Bernstin L, et al. (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66: 8297-308.
31. Ademuyiwa FO, Edge SB, Erwin DO, Orom H, Ambrosone CB, et al. (2011) Breast cancer racial disparities: unanswered questions. Cancer Res 71: 640-4.
32. Terplan M, Schluterman N, McNamara EJ, Tracy JK, Temkin SM (2011) Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol Nov 21 [Epub ahead of print].
33. Ikegami H, Kawabata Y, Noso S, Fujisawa T, Ogihara T, (2007) Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res Clin Pract 77Suppl 1: S116-21.
34. Gleicher N, Siegel I, Francus K, (1980) Common denominators of pregnancy and malignancy. Mt Sinai J Med 47: 511-520.
35. Gleicher N, Siegel I, (1981) Common denominators of pregnancy and malignancy. Prog Clin Biol Res 70: 339-353.